Search
Displaying 541–550 of 689 for “retinitis clinical trial”
-
Research News
At VISIONS 2016, FFB’s national conference, the Foundation honored him with its Ed Gollob Board of Directors Award for breakthrough research conducted within the past year.
-
Beacon Stories
An interview with Louis Posen, record label founder and retinitis pigmentosa patient.
-
Lighting a Candle: The Author of a New Memoir Shares the Highs and Lows of Vision Loss
Beacon StoriesNicole Simpson, author of “Now I See You,” shares her experience with retinitis pigmentosa.
-
Just How Tricky Halloween Can Be
Beacon StoriesFor those with night blindness, a symptom of many retinal diseases, most notably retinitis pigmentosa, or RP, navigating a trick-or-treating throng can be, well, a nightmare.
-
Alice Bartlett – Back on That Horse
Beacon StoriesHis name is Battle. He’s an Arabian, stands more than 15 hands (or 5 feet) tall and weighs 1,000 pounds. He’s been with Alice Bartlett since his birth 26 years ago, and she’s been riding him since he was 2.
Alice, by the way, is legally blind.
-
RetNet: A Web-Based Guide to Every Retinal Disease Gene Known to Man
Research NewsCheck out RetNet, the online catalogue of every known retinal degenerative disease gene.
-
Research News
Thanks to recent advances in stem cell research, we are getting closer to replacing cells in the retina lost to diseases such as retinitis pigmentosa and age-related macular degeneration.
-
Eye on the Cure Podcast | Episode 88: Richard Small
Eye on the CureRichard Small, CEO of Neurotech, talks to host Ben Shaberman about ENCELTO™, the first and only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2 (MacTel).
-
Honoring the Legacy of Bob Reintsma: A Visionary in the Fight Against Blinding Diseases
Foundation NewsBob Reintsma was fiercely passionate about driving treatments and cures for blinding diseases for most of his life. The Foundation is extremely grateful for Bob’s dedication to our mission and legacy of generosity.
-
Eye on the Cure Podcast | Episode 82: Aaron Nagiel, MD, PhD
Eye on the CureDr. Nagiel discusses how gene therapy is administered to the retina, the surgery and recovery for patients, and the vision improvements for young patients receiving LUXTURNA, the first FDA-approved gene therapy for the eye or an inherited condition.
.png)
